Abstract
Sleep Disorders (SDs) precede motor symptoms of Parkinson’s disease (PD), suggesting an early effect of disease processes on sleep control neurons. PD processes involve rises in the protein, α-synuclein, which presents early on in a simple, monomeric form, but later in disease progression, a more complex fibril form appears. We hypothesize that monomeric α-synuclein has deleterious cellular actions on sleep control nuclei. We monitored cellular responses to identified monomeric and fibril α-synuclein in two sleep controlling nuclei, the laterodorsal tegmentum, and the pedunculopontine tegmentum, as well as the substantia nigra, a motor control nucleus which degenerates as a hallmark PD feature. We monitored differential cell death using a fluorescent-based assay following exposure to the simpler form of α-synuclein. In sleep control nuclei, both forms of intrinsic α-synuclein induced excitation, and increased intracellular calcium and the monomeric form heightened putatively excitotoxic, neuronal death, whereas, in the substantia nigra we saw inhibition, decreased intracellular calcium and monomeric α-synuclein was not associated with heightened cell death. These nucleus-specific differential effects suggest previously unappreciated, mechanistic underpinnings of SDs’ prodromal PD appearance in PD, and we hypothesize that in the prodromal phase of PD, the early form of α-synuclein compromises sleep-control neurons.
Management of sleep disorders in Parkinson's disease
